Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels

Archives of Internal Medicine

Volumn 156, Issue 10, 1996, Pages 1081-1088

  Martin Jadraque, Raquel ^a   Tato, Federico ^a   Mostaza, Jose M ^a   Vega, Gloria Lena ^a,c   Grundy, Scott M ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DRUG FORMULATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MIGRAINE; PRIORITY JOURNAL; SKIN MANIFESTATION;

CRYSTALLIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIAS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NICOTINIC ACIDS; TREATMENT OUTCOME;

EID: 0029924834     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.10.1081     Document Type: Article

References (50)

1. Parsons WB Jr. Studies of nicotinic acid use in hypercholesterolemia: changes in hepatic function, carbohydrate tolerance and uric acid metabolism. Arch Intern Med. 1961;107:85-99.
2. Parson WB Jr. Treatment of hypercholesterolemia by nicotinic. Arch Intern Med. 1961;107:639-652.
3. Carlson LA, Oro L Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis. 1973;18:1-9.
4. Carlson LA, Froberg S, Oro L. A case of massive hypertriglyceridemia corrected by nicotinic acid or nicotinamide therapy. Atherosclerosis. 1972;16:359-368.
5. Knoop RH, Ginsberg J, Albers JJ. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-650.
6. Luria MH. The effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein ratio. Arch Intern Med. 1988; 148:2493-2495.
7. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Nonrad S, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high-density lipoprotein cholesterol and the cholesterol to high-density lipoprotein ratio. Am J Cardiol. 1989;64:725-729.
8. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 1992;69:1083-1085.
9. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
10. Drood JM, Zimetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol. 1991;31:641-650.
11. Yovos JG, Patel ST, Falko JM, Newman HA, Hill DS. Effects of nicotinic acid therapy on plasma lipoproteins and very-low-density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. J Clin Endocrinol Metab. 1982;54:1210-1215.
12. Charmon RC, Matthews LB, Braeuler C. Nicotinic acid in the treatment of hypercholesterolemia: a long-term study. Angiology. 1972;23:29-35.
13. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
14. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73-82.
15. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62:707-714.
16. Castelli WP, Garrison RJ, Wilson PWF, Abbot RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framing-ham Study. JAMA. 1986;256:2835-2838.
17. Miller M, Mead LA, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol. 1990;65:1-5.
18. Lavie CJ, Milani RV. National Cholesterol Education Program's recommendations, and implications of 'missing' high-density lipoprotein cholesterol in cardiac rehabilitation programs. Am J Cardiol. 1991;68:1087-1088.
19. Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels. Am J Cardiol. 1991;68:187-192.
20. Genest JJ, McNamara JR, Salem DN, Schaefer EJ, Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185-1189.
21. Vega GL, Grundy SM. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA. 1989;262:3148-3153.
22. Roeschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem. 1974;12:226-227.
23. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29: 538-542.
24. Assman G, Schriewer H, Schmitz G, Haegele E. Quantification of high-density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgC12. Clin Chem. 1983;29:2026-2030.
25. Warnick GR, Cheung MC, Albers JJ. Comparison of current methods for high-density lipoprotein cholesterol quantitation. Clin Chem. 1979;25:596-604.
26. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Bethesda, Md: US Government Printing Office; 1984:F5.
27. Lipid Research Clinics Program. Manual of Laboratory Procedures: Lipid and Lipoprotein Analyses. Bethesda, Md: US Government Printing Office; 1975:1: 51.
28. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins in blood lipids and lipoproteins. In: Nelson GS, ed. Quantification, Composition and Metabolism. New York, NY: John Wiley & Sons Inc; 1972:181-274.
29. Vega GL, Grundy SM. Comparison of apolipoprotein B to cholesterol in low-density lipoprotein of patients with coronary heart disease. J Lipid Res. 1984; 25:580-592.
30. Marcovina SM, Albers JJ. International Federation of Clinical Chemistry Study on the standardization of apolipoproteins A-I and B. Curr Opin Lipidol. 1991; 2:355-361.
31. Laurell CB. Electroimmunoassay. Scand J Lab Invest. 1972;124:21-37.
32. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1995; 15:112-120.
33. Blades B, Vega GL, Grundy SM. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb Vasc Biol. 1993;13:1227-1235.
34. Chen C, Albers JJ. Characterization of proteoliposomes containing apolipoprotein A-I: a new method for the measurement of lecithin: cholesterol acyltransferase activity. J Lipid Res. 1982;23:680-691.
35. Winer BJ. Statistical Principles in experimental Design. New York, NY: McGraw-Hill International Book Co; 1971:114.
36. Schmilz G, Williamson E. High-density lipoprotein metabolism, reverse cholesterol transport and membrane protection. Curr Opin Lipidol. 1991;2:177-189.
37. Tall AR. Plasma high-density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
38. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low-density lipoprotein aggregation by high-density lipoprotein or apolipoprotein A-I. J Lipid Res. 1990;31:645-658.
39. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990; 1044:275-283.
40. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;B2:1916-1924.
41. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112-1119.
42. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
43. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
44. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
45. Frick MH, Elo MO, Haapa K. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317: 1237-1245.
46. Grundy SM, Vega GL Influence of mevinolin on metabolism of low-density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res. 1985;26: 1464-1475.
47. Blankenhorn DH, Nessim SA, Johnson RD, Sanmarco MER, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257: 3233-3240.
48. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
49. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
50. Davignon J, Roederer G, Montigny M, et al. Comparison of efficacy and safety of pravastatin, nicotinic acid, and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994;73:339-345.